溶瘤病毒作为抗肿瘤药治疗肝癌的研究进展

Research advance in oncolytic viruses as anticancer agents for hepatocellular carcinoma

肝癌是全球第六大最常诊断的癌症,也是第三大最常见的癌症死亡原因,据相关数据推测,预计到2025年,每年将有超过100万人受到肝癌的影响。现有的指南推荐治疗方案,仍然无法根治肝癌,临床也仍然面临着高复发率、高死亡率、高转移率等窘境。采用溶瘤病毒作为治疗肿瘤的药物,是一种全新的治疗方式,具有一定的可行性。溶瘤病毒是天然存在或经过改造的病毒,其具有高选择性地复制和诱导细胞病变效应的能力,这些特性使它们非常适合用于癌症的治疗。本文通过对目前的溶瘤病毒种类及其作用机制,目前存在的问题,进行归纳整理。以期能为肝癌的治疗研究提供参考,同时对于拓展新的疗法,帮助更多的患者具有重要意义。

Liver cancer is the sixth most commonly diagnosed cancer worldwide and the third most common cause of cancer death,and is expected to affect more than 1 million people annually by 2025.The existing guideline recommended treatment plan,still can not provide complete cure for liver cancer,and clinical doctors still face high recurrence rate,high mortality,high metastasis rate and other problems.Oncolytic viruses are naturally existing or modified viruses.Oncolytic viruses can selectively replicate and induce cytopathic effects.These characteristics make them very suitable for cancer.This paper summarized the types,mechanism and existing problems of oncolytic viruses,aiming to provide reference for the treatment of liver cancer,developing new therapies and helping more patients.